Therapeutic Approaches of Angiogenesis Inhibition: Are We Tackling the Problem at the Right Level?

Trends in Cardiovascular Medicine

Volumn 17, Issue 5, 2007, Pages 171-176

  Griffioen, Arjan W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINEX; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CARBOPLATIN; ENDOSTATIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; PPI 2458; RITUXIMAB; SUNITINIB; TRASTUZUMAB; TUMSTATIN; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CANCER RESISTANCE; CLINICAL TRIAL; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; HUMAN; INHIBITION KINETICS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANGIOGENESIS INHIBITORS; COLORECTAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 34250195797     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2007.03.007     Document Type: Review

References (39)

1. Brandwijk R.J., Nesmelova I., Dings R.P., et al. Cloning an artificial gene encoding angiostatic anginex: from designed peptide to functional recombinant protein. Biochem Biophys Res Commun 333 (2005) 1261-1268
2. Brandwijk R.J., Dings R.P., Van der Linden E., et al. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun 349 (2006) 1073-1078
3. Collins I., and Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2 (2006) 689-700
4. Dawson D.W., Pearce S.F., Zhong R., et al. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138 (1997) 707-717
5. Dings R.P., Nesmelova I., Griffioen A.W., and Mayo K.H. Discovery and development of anti-angiogenic peptides: a structural link. Angiogenesis 6 (2003) 83-91
6. Dings R.P., Yokoyama Y., Ramakrishnan S., et al. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 63 (2003) 382-385
7. Dings R.P., Chen X., Hellebrekers D.M., et al. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst 98 (2006) 932-936
8. Ferrara N., Hillan K.J., Gerber H.P., et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
10. Folkman J. Angiogenesis. Annu Rev Med 57 (2006) 1-18
11. Griffioen A.W., and Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52 (2000) 237-268
12. Griffioen A.W., Van der Schaft D.W., Barendsz-Janson A.F., et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 354 (2001) 233-242
13. Griffith E.C., Su Z., Turk B.E., et al. Methionine aminopeptidase (type 2) is thecommon target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 4 (1997) 461-471
14. Hendrix M.J., Seftor E.A., Hess A.R., and Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3 (2003) 411-421
15. Hida K., and Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65 (2005) 2507-2510
16. Karumanchi S.A., Jha V., Ramchandran R., et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 7 (2001) 811-822
17. Lucerna M., Zernecke A., de Nooijer R., et al. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood 109 (2007) 122-129
18. Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8 (2002) 831-840
19. Madden S.L., Cook B.P., Nacht M., et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 165 (2004) 601-608
20. Mayo K.H., Ilyina E., and Park H. A recipe for designing water-soluble, beta-sheet-forming peptides. Protein Sci 5 (1996) 1301-1315
21. Mayo K.H., Dings R.P., Flader C., et al. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem 278 (2003) 45746-45752
22. Moser T.L., Stack M.S., Asplin I., et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 96 (1999) 2811-2816
23. Moulton K.S. Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr Opin Lipidol 17 (2006) 548-555
24. Moulton K.S., Heller E., Konerding M.A., et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99 (1999) 1726-1732
25. Parker B.S., Argani P., Cook B.P., et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 64 (2004) 7857-7866
26. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 22 (2004) 1198
27. Rehn M., Veikkola T., Kukk-Valdre E., et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 98 (2001) 1024-1029
28. St Croix B., Rago C., Velculescu V., et al. Genes expressed in human tumor endothelium. Science 289 (2000) 1197-1202
29. Streubel B., Chott A., Huber D., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351 (2004) 250-259
30. Thijssen V.L., Postel R., Brandwijk R.J., et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 103 (2006) 15975-15980
31. Van Beijnum J.R., and Griffioen A.W. In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. Biochim Biophys Acta 1755 (2005) 121-134
32. Van Beijnum J., Dings R.P., Van der Linden E., et al. Gene expression of tumor angiogenesis dissected; specific targeting of colon cancer angiogenic vasculature. Blood 108 (2006) 2339-2348
33. Van der Schaft D.W., Dings R.P., de Lussanet Q.G., et al. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 16 (2002) 1991-1993
34. Van der Schaft D.W., Hillen F., Pauwels P., et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 65 (2005) 11520-11528
35. Van der Schaft D.W., Seftor R.E., Seftor E.A., et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96 (2004) 1473-1477
36. Virmani R., Kolodgie F.D., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 25 (2005) 2054-2061
37. Wang Y., Fei D., Vanderlaan M., and Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7 (2004) 335-345
38. Wickstrom S.A., Alitalo K., and Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 62 (2002) 5580-5589
39. Yu Y., Moulton K.S., Khan M.K., et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci US A 101 (2004) 8005-8010